The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Is gilteritinib the new breakthrough in the treatment of FLT3-mutated AML?
Mark Levis, MD, PhD, from John Hopkins University, Baltimore, MD, USA, presents us with an insight on how gilteritinib, a next-generation FLT3 inhibitor, is superior over previous FLT3 inhibitors in treating FLT3-mutated acute myeloid leukemia (AML). He also details the difficulty in quantifying responses from patients with relapsed FLT3-mutated AML who have been treated with a single agent, but adds that his team have developed an assay using next-generation sequencing that has allowed them to overcome these issues. He concludes with a statement on the recent retrieval of Phase I/II trial data (NCT02014558) focused on the study of gilteritinib in treating FLT-mutated AML and adds that the drug is now undergoing Phase III trials. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
